Trending Stock News

Ls Investment Advisors Has Lifted By $328,202 Its Core Laboratories N V (CLB) Position; Harvard Bioscience Has 0.91 Sentiment

Ls Investment Advisors Llc increased Core Laboratories N V (CLB) stake by 370.46% reported in 2017Q3 SEC filing. Ls Investment Advisors Llc acquired 3,349 shares as Core Laboratories N V (CLB)’s stock declined 4.78%. The Ls Investment Advisors Llc holds 4,253 shares with $420,000 value, up from 904 last quarter. Core Laboratories N V now has $4.67B valuation. The stock increased 0.24% or $0.25 during the last trading session, reaching $105.75. About 984,270 shares traded or 85.38% up from the average. Core Laboratories N.V. (NYSE:CLB) has declined 5.82% since February 15, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $156.96 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

It closed at $4.5 lastly. It is down 25.93% since February 15, 2017 and is downtrending. It has underperformed by 42.63% the S&P500.

Glacier Peak Capital Llc holds 5.69% of its portfolio in Harvard Bioscience, Inc. for 1.33 million shares. First Light Asset Management Llc owns 4.12 million shares or 4.89% of their US portfolio. Moreover, Bard Associates Inc has 0.61% invested in the company for 348,872 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.48% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 540,819 shares.

Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on March, 8. They expect $0.03 earnings per share, up 200.00% or $0.02 from last year’s $0.01 per share. HBIO’s profit will be $1.05 million for 37.50 P/E if the $0.03 EPS becomes a reality. After $0.01 actual earnings per share reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

Ls Investment Advisors Llc decreased Verizon Communications (NYSE:VZ) stake by 24,257 shares to 126,661 valued at $6.27M in 2017Q3. It also reduced Stryker Corp (NYSE:SYK) stake by 6,721 shares and now owns 9,895 shares. C.H. Robinson Worldwide (NASDAQ:CHRW) was reduced too.

Leave a Reply

Your email address will not be published. Required fields are marked *